Therapy for Human Endometrioid - Endometrial Carcinoma and Endometriosis
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (20 September 2022) | Viewed by 28506
Special Issue Editor
Interests: tight junctions; p63; pathophysiology; cell biology; molecular pathology; oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Endometrial cancer is the most common malignancy among diseases affecting women, and the incidence is rising in high-income countries. Therefore, further elucidation of the pathophysiology of endometrial cancer is needed to develop new treatments. Endometrial carcinoma is classified into two clinicopathological types (Type I and Type II). Type I endometrial carcinoma is the most common subtype, accounting for >80% of endometrial tumors. The relation between diabetes and endometrial cancer is controversial, and diabetes may contribute to endometrial cancer progression. Endometriosis causes chronic pelvic pain, dysmenorrhea, and infertility in women. Endometrioid endometrial adenocarcinoma arising from endometriosis is rare in premenopausal women.
However, recent advances in understanding the genetic and epigenetic alterations including cell–cell interaction that underlie endometrioid–endometrial Carcinoma and Endometriosis provide novel approaches to their treatment. The Special Issue on “Therapy for Human Endometrioid–Endometrial Carcinoma and Endometriosis” will comprise a selection of original research papers and reviews focusing on the molecular mechanisms and the pathophysiology of human endometrioid–endometrial carcinoma and endometriosis for the development of novel therapeutic approaches.
Prof. Dr. Takashi Kojima
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endometrioid–endometrial carcinoma
- endometriosis
- endometrial hyperplasia
- endometrial stromal cells
- EMT
- malignancy
- cell–cell interaction
- obesity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.